Jan Orwar
Directeur/Membre du Conseil chez FLUICELL AB
Profil
Jan Owe Owesson Orwar is the founder.
He founded Cellectricon AB in 2000, where he held the title of Director & Chief Scientific Officer.
He also founded Nanoxis AB in 2002, where he held the title of Director & Chief Scientific Advisor until 2014.
Dr. Orwar is also the founder of Oblique Therapeutics AB.
Dr. Orwar's current job(s) include being the Director-Bioeletronics & Bio-Computing Program at Chalmers University of Technology since 2011.
He is also the Director at Fluicell AB since 2015 and a Senior Group Leader at Karolinska Institutet.
Dr. Orwar's former job(s) include being the President-Research & Development at Piramal Enterprises Ltd.
and the Global Vice President-Research & Development at Sanofi AB.
Dr. Orwar obtained a doctorate degree from Stanford University and the University of Gothenburg.
Postes actifs de Jan Orwar
| Sociétés | Poste | Début |
|---|---|---|
| FLUICELL AB | Directeur/Membre du Conseil | 01/01/2015 |
| Chalmers University of Technology | Corporate Officer/Principal | 17/01/2011 |
| Karolinska Institutet | Corporate Officer/Principal | - |
Anciens postes connus de Jan Orwar
| Sociétés | Poste | Fin |
|---|---|---|
Nanoxis AB
 Nanoxis AB Miscellaneous Commercial ServicesCommercial Services Nanoxis AB provides tools and services for membrane protein research. It specializes in research and development of nanofabrication technologies in soft polymer and fluid-state liquid crystalline material. The company was founded by Owe Orwar and Anders Karlsson in November 2002 and is headquartered in Gothenburg, Sweden. | Fondateur | 11/02/2014 |
| PIRAMAL ENTERPRISES LIMITED | Directeur Technique/Scientifique/R&D | - |
Sanofi AB
 Sanofi AB Medical DistributorsDistribution Services Part of Sanofi, Sanofi AB is a pharmaceutical company based in Stockholm, Sweden. The Swedish company's description states that it is an international pharmaceutical company. | Directeur Technique/Scientifique/R&D | - |
Oblique Therapeutics AB
 Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Directeur Général | - |
Cellectricon AB
 Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Fondateur | - |
Formation de Jan Orwar
| University of Gothenburg | Doctorate Degree |
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PIRAMAL ENTERPRISES LIMITED | Finance |
| FLUICELL AB | Health Technology |
| Entreprise privées | 4 |
|---|---|
Cellectricon AB
Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Commercial Services |
Nanoxis AB
Nanoxis AB Miscellaneous Commercial ServicesCommercial Services Nanoxis AB provides tools and services for membrane protein research. It specializes in research and development of nanofabrication technologies in soft polymer and fluid-state liquid crystalline material. The company was founded by Owe Orwar and Anders Karlsson in November 2002 and is headquartered in Gothenburg, Sweden. | Commercial Services |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Health Technology |
Sanofi AB
Sanofi AB Medical DistributorsDistribution Services Part of Sanofi, Sanofi AB is a pharmaceutical company based in Stockholm, Sweden. The Swedish company's description states that it is an international pharmaceutical company. | Distribution Services |
